For decades, most African nations have relied heavily on imported pharmaceuticals to meet their medical needs. In this analysis, pharmacist and engineer Dr. Arnaud Kaboré outlines a strategic roadmap for African policymakers to achieve health sovereignty by 2045.

Why overdependence on foreign pharmaceuticals poses a growing risk

Today, fewer than five African countries operate manufacturing facilities capable of exporting beyond their borders. This chronic dependence leaves the continent importing 94% of its medicines at an annual cost exceeding $18 billion—a figure projected to rise above $30 billion by 2030. While the economic burden is severe, the true cost lies in structural vulnerability: medical supply chains controlled from outside the continent.

Public health systems across Africa report critical drug shortages at least once per quarter. Is it sustainable for 1.4 billion Africans to depend on industrial, logistical, and geopolitical decisions made beyond their borders? The Covid-19 pandemic exposed these risks: shortages of essential drugs like amoxicillin, insulin, and anesthetics, skyrocketing prices during shortages, and chronic inaccessibility to cancer treatments and innovative therapies. These failures have real consequences—delayed treatments, multiplied costs, and stalled public health programs.

Yet Africa possesses untapped potential:

• A rapidly expanding pharmaceutical market projected to surpass $70 billion by 2030;
• Over 5,400 documented medicinal plants, some already integrated into official therapeutic protocols;
• Progress in regulatory alignment through the African Medicines Agency (AMA), now ratified by 27 nations;
• Bold leadership in countries like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa, which have launched ambitious local production initiatives.

Building Africa’s pharmaceutical future: a sustainable path forward

One of Africa’s historic missteps has been attempting to replicate the models of international